• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Oragenics Inc.

    3/19/26 5:24:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    S-3/A 1 forms-3a.htm S-3/A

     

    As filed with the Securities and Exchange Commission on March 19, 2026

     

    Registration No. 333-292880

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Pre-Effective Amendment No. 1 to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    ORAGENICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Florida   59-3410522

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    9015 Town Center Parkway, Suite 143

    Lakewood Ranch, Florida 34202

    (813) 286-7900

    (Address, including zip code, and telephone number, including area code, of principal executive offices)

     

     

     

    Janet Huffman

    Chief Executive Officer

    Oragenics, Inc.

    9015 Town Center Parkway, Suite 143

    Lakewood Ranch, Florida 34202

    (813) 286-7900

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    With copies to:

     

    Mark A. Catchur, Esq.

    Julio Esquivel, Esq.

    Shumaker, Loop & Kendrick, LLP

    101 East Kennedy Boulevard, Suite 2800

    Tampa, Florida 33602

    Telephone: (813) 229-7600

     

    Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
       
    Non-accelerated filer ☒ Smaller reporting company ☒
       
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that the Registration Statement shall thereafter become effective in accordance with Section 8(A) of the Securities Act of 1933, or until this registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    We are filing this pre-effective amendment (the “Amendment”) to our Registration Statement on Form S-3, as amended (File No. 333-292880), initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2026 (the “Registration Statement”), as an exhibits-only filing to file an updated auditor consent in Exhibit 23.1. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, including the signature page and the exhibit index, and the filed exhibits. The prospectus is unchanged and has been omitted.

     

     

     

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibit Index

     

    Exhibit

    number

      Exhibit description   Form   File no.   Exhibit   Filing date   Filed herewith
    1.1*   Form of Underwriting Agreement                    
                             
    3.1   Amended and Restated Articles of Incorporation as amended prior to December 29, 2017 (including certificates of designation of Series A, B and C Preferred Stock)   8-K   001-32188   3.1   12/29/17    
                             
    3.2   Articles of Amendment to Amended and Restated Articles of Incorporation dated effective December 29, 2017   8-K   001-32188   3.2   12/29/17    
                             
    3.3   Articles of Amendment to Amended and Restated Articles of Incorporation effective January 19, 2018   8-K   001-32188   3.1   1/19/18    
                             
    3.4   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.4   6/26/18    
                             
    3.5   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.5   2/28/22    
                             
    3.6   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   1/23/2023    
                             
    3.7   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   8/7/2023    
                             
    3.8   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   12/8/2023    
                             
    3.9   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   12/15/2023    
                             
    3.10   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   5/28/2025    
                             
    3.11   Articles of Amendment to Amended and Restated Articles of Incorporation   8-K   001-32188   3.1   7/2/2025    
                             
    3.12   Bylaws   SB-2   333-100568   3.2   10/16/02    
                             
    3.13   First Amendment to Bylaws   8-K   001-32188   3.1   6/9/10    
                             
    3.14   Second Amendment to Bylaws   8-K   001-32188   3.1   8/24/10    
                             
    3.15   Third Amendment to Bylaws   8-K   001-32188   3.9   2/28/22    
                             
    4.1   Specimen Stock Certificate   8-K   001-32188   4.1   1/23/23    
                             
    4.2*   Form of Warrant                    
                             
    4.3*   Form of Warrant Agreement                    
                             
    4.4*   Form of Unit                    
                             
    4.5*   Form of Unit Agreement                    
                             
    5.1   Opinion of Shumaker, Loop & Kendrick, LLP   S-3   333-292880   5.1   1/22/26    
                             
    23.1   Consent of Cherry Bekaert LLP, an Independent Public Accounting Firm   S-3/A   333-292880           X
                             
    23.2   Consent of Shumaker, Loop & Kendrick, LLP (included in Exhibit 5.1)   S-3   333-292880   23.2   1/22/26    
                             
    24.1   Powers of Attorney (included on signature page).   S-3   333-292880   24.1   1/22/26    
                             
    107   Filing Fee Table   S-3   333-292880   107   1/22/26    

     

    * To be filed by amendment or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and incorporated herein by reference.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this pre-effective amendment no. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tampa, State of Florida on March 19, 2026.

     

      ORAGENICS, INC.
         
      By: /s/ Janet Huffman
        Janet Huffman
        President, Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities indicated and on March 19, 2026.

     

    Signature   Title
         
    /s/ Janet Huffman   President, Chief Executive Officer (Principal Executive Officer) and
    Janet Huffman   Chief Financial Officer (Principal Financial Officer)
         
    *   Chairman and Director
    Charles L. Pope    
         
    *   Director
    Robert C. Koski    
         
    *   Director
    Frederick W. Telling    
         
    *   Director
    Alan W. Dunton    
         
    *   Director
    John Gandolfo    
         
    *   Director
    Natasha Giordano    

     

     

     

    Get the next $OGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman Sachs initiated coverage on Oragenics with a new price target

    Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

    6/3/21 6:23:39 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Telling Fred sold $198 worth of shares (210 units at $0.94), decreasing direct ownership by 18% to 948 units (SEC Form 4)

    4/A - ORAGENICS INC (0001174940) (Issuer)

    1/22/26 1:04:30 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and CFO Huffman Janet

    4 - ORAGENICS INC (0001174940) (Issuer)

    12/15/25 4:55:39 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Giordano Natasha

    4 - ORAGENICS INC (0001174940) (Issuer)

    12/15/25 4:49:15 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

    REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The Annual Report on Form 10-K, including audited financial statements fo

    3/17/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

    FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The visit marks the formal launch of clinical trial operations at the first of three planned trial sites in Australia, including completion of site staff training, protocol orientation, and site regulatory documentation. The remaining two clinical trial sites are currently completing their Research Govern

    3/12/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

    SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company's lead candidate ONP-002 and its proprietary intranasal drug delivery platform. The Company's portfolio expansion initiative is being pursued independently of its existing partnership with Recepto

    3/11/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Oragenics Inc.

    S-3/A - ORAGENICS INC (0001174940) (Filer)

    3/19/26 5:24:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Oragenics Inc.

    10-K - ORAGENICS INC (0001174940) (Filer)

    3/16/26 4:30:41 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Oragenics Inc.

    8-K - ORAGENICS INC (0001174940) (Filer)

    3/11/26 4:26:03 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Financials

    Live finance-specific insights

    View All

    Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

    TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

    2/12/21 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

    SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

    2/24/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

    SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

    5/22/24 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Oragenics Inc.

    SC 13G - ORAGENICS INC (0001174940) (Subject)

    9/11/24 7:45:36 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care